Medrobotics, an emerging medical robotics company developing the Flex™ Robotic System, announced today the appointment of Eugene N. Myers, M.D., and Marshall Strome, M.D., two thought-leaders in the field of head and neck surgery, as co-chairmen of the company’s worldwide Medical Advisory Board.
“The Flex™ Robotic System is designed to provide hospitals with a cost‐effective, multi‐purpose surgical platform so they can offer patients and surgeons a new, minimally-invasive treatment alternative for disease in difficult-to-access anatomical locations, starting with trans-oral applications in the oropharynx and larynx,” said Samuel Straface, Ph.D., president and CEO of Medrobotics. “We are extremely excited to have Dr. Myers and Dr. Strome, two exceptional surgeons, lead our worldwide Medical Advisory Board as we prepare to make our first product available to leading head and neck surgeons,” added Dr. Straface.
Dr. Eugene N. Myers is Distinguished Professor and Emeritus Chair of the Department of Otolaryngology at the University of Pittsburgh School of Medicine. He has written 259 articles and has published many books, the most notable of which is Cancer of the Head and Neck together with Dr. James Y. Suen, now considered the standard textbook on this topic. Dr. Myers serves on many editorial boards throughout the world and was International Editor of Otolaryngology-Head and Neck Surgery. “I am excited to participate in making this important technology available to surgeons and their patients, whose treatment options currently are often limited and not well tolerated,” said Dr. Myers.
Dr. Marshall Strome is the immediate past Professor and Chairman of the Cleveland Clinic Head and Neck Institute. In 1998, Dr. Strome performed the world’s first total human laryngeal transplant; and in 2005, he performed the world’s first robotic laser excision of a laryngeal malignancy. In addition to more than 200 publications and several books, Dr Strome was one of a select group of physicians recognized at the millennium by the American Academy of Otolaryngology Head and Neck Surgery for their contributions to medicine in the last 250 years.
The initial application of the Flex™ Robotic System will address a compelling unmet need for minimally invasive treatment options for the approximately 200,000 patients diagnosed with head and neck cancer each year in the U.S. and Europe, and many more with significant benign disease. The system is anticipated to be commercially available in 2013 in the U.S. and Europe. Additional applications in other difficult-to-access anatomical locations in the body are already under development.